Brief: Ose Immunotherapeutics Receives New Approval For Early Access Program For Tedopi In Spain
01/03/2023 06:31
March 1 (Reuters) - OSE Immunotherapeutics SA OSE.PA :
* OSE IMMUNOTHERAPEUTICS RECEIVES NEW APPROVAL FOR AN EARLY
ACCESS
PROGRAM FOR TEDOPI® IN SPAIN IN NON-SMALL CELL LUNG CANCER AFTER
FAILURE TO IMMUNOTHERAPIES
Source text for Eikon: ID:nBw7kkqYRa
Further company coverage: OSE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO